Participants in this study will receive dazukibart, which is a type of medication known as a monoclonal antibody. This medication is designed to target and neutralize specific proteins in the body that may contribute to inflammation. The study will also involve other medications, including betamethasone, hydroxychloroquine, chloroquine phosphate, hydrocortisone, triamcinolone acetonide, methylprednisolone, mycophenolate mofetil, budesonide, dexamethasone, azathioprine, prednisolone, methotrexate, deflazacort, leflunomide, and prednisone. Some participants may receive a placebo instead of the active medication.

The study will last for up to 52 weeks, during which participants will be monitored for any side effects and changes in their condition. The goal is to gather information on the safety of dazukibart and its effectiveness in managing symptoms of idiopathic inflammatory myopathies. Participants will undergo regular check-ups and assessments to track their progress and any changes in their health status.

The purpose of the study is to determine if Anifrolumab can provide a moderate improvement in disease activity over a period of 52 weeks. Participants will receive either Anifrolumab or a placebo through subcutaneous injections, which means the medication is injected under the skin. The study will follow a double-blind method, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo, to ensure unbiased results.

Throughout the study, participants will continue their usual treatments for Polymyositis or Dermatomyositis, and their progress will be monitored to assess any changes in their condition. The trial aims to provide valuable information on whether Anifrolumab can be a beneficial addition to the current standard of care for these conditions.

The purpose of the study is to assess whether patients can maintain stable disease activity without the need for intravenous immunoglobulins (IVIG), a common treatment for these conditions. Participants in the study will be randomly assigned to receive either Upadacitinib or a placebo, which is a substance with no active medication. The study will last for a period of 20 weeks, during which the participants’ health and disease activity will be closely monitored. The main goal is to see if patients can remain stable without IVIG by the 16th week of the study.

Throughout the trial, various aspects of the participants’ health will be evaluated, including muscle strength, quality of life, and any side effects experienced. The study will also compare the time it takes for symptoms to worsen between those taking Upadacitinib and those taking the placebo. This research aims to provide valuable insights into the potential of Upadacitinib as a treatment option for individuals with idiopathic inflammatory myopathies, potentially reducing the need for IVIG and improving overall management of these conditions.

The purpose of this study is to evaluate the safety and the relationship between the body’s immune response and the clinical outcomes when using low-dose IL-2 therapy in patients with these diseases. Participants will receive the treatment over a period of eight weeks. The study is designed to be randomized, meaning participants will be randomly assigned to different groups, and double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or a placebo. This helps ensure the results are unbiased.

Throughout the study, researchers will monitor the participants’ immune responses and any changes in their disease symptoms. The goal is to understand how the treatment affects the immune system and whether it leads to improvements in the conditions being studied. The trial will help determine if low-dose IL-2 therapy is a safe and effective option for managing these chronic inflammatory diseases.

The study will also involve other medications that are commonly used to manage these conditions, such as methotrexate, azathioprine, and various glucocorticosteroids like methylprednisolone, dexamethasone, and prednisone. These medications help reduce inflammation and suppress the immune system. The trial will last for about a year, during which participants will receive regular treatments and assessments to monitor their muscle symptoms and overall health.

The purpose of this study is to determine if PF-06823859 can effectively reduce muscle symptoms in adults with active dermatomyositis or polymyositis. Participants will be randomly assigned to different groups to receive either the study medication or a placebo, and their progress will be closely monitored by healthcare professionals. The study will help researchers understand the potential benefits and risks of this new treatment option for people living with these challenging muscle conditions.

The study will be conducted over a period of 48 weeks. During this time, participants will be randomly assigned to receive either Enpatoran or a placebo. The trial is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure that the results are not biased. The main focus will be on the improvement of symptoms and the safety of the treatment.

Throughout the study, participants will have regular check-ups to monitor their health and any changes in their condition. These check-ups will include assessments of muscle strength and skin condition, as well as routine laboratory tests to ensure the safety of the treatment. The study aims to provide valuable information on whether Enpatoran can be a beneficial treatment option for those living with Dermatomyositis and Polymyositis.